潘瑞艳 | ||
|
||
作者: 发表时间:2020-04-28 |
|
|
一、基本情况介绍 潘瑞艳,女,群众,讲师,博士。 二、教学工作 承担《药理学》《药理学研究方法》等课程教学工作。 三、科研工作 1、主持或参加科研项目(限5项以内) [1] 基于TLR4/NF-κB/TGF-β1通路探讨羟基红花黄色素A改善糖尿病肾病的作用,山东省自然科学博士基金项目,ZR2019BH036,10万元,2019-07至2022-06,在研,主持 [2]羟基红花黄色素A对糖尿病肾病大鼠NF-κB信号通路的影响,潍坊市科学技术发展计划项目,2018YX058,0万元,2018至2021,在研,主持 [3]基于肾周脂肪棕色化-SIRT1-HO-1/脂联素轴正反馈环路探讨Irisin保护肥胖相关性肾病的研究,国家自然科学基金面上项目,81870593,57万元,2019-01至2022-12,在研,参加 [4]XPC/Snail通路对肺癌干细胞亚群的影响及调控机制研究,国家自然科学基金面上项目,81871892,25万元,2019-01至2020-12,结题,参加 2、代表性论著(限5项以内) [1] Yusha Chen#, Ruiyan Pan#, Juanjuan Zhang#, Tianming Liang, Juan Guo, Tai Sun, Xiaoyan Fu, Ling Wang, Lane Zhang*. Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats. J Ethnopharmacol,2021,272:113920. [2] Bo Lian#, Hua Wei#, Ruiyan Pan#, Jingui Sun, Bo Zhang, Jingliang Wu, Xiujie Li*, Guixiang Tian*. Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4.Int J Nanomedicine,2021,16:457-467. [3] Xue Han, Chuanhua Ding, Guangdong Zhang, RuiYan Pan,Yongping Liu, Na Huang, Ningning Hou, Fang Han, Wenjie Xu, Xiaodong Sun*. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway. Biochemical and Biophysical Research Communications,2020,525(4):895-901. [4] Guixiang Tian#, Ruiyan Pan#, Bo Zhang#, Meihua Qu, Bo Lian, Hong Jiang, Zhiqin Gao*, Jingliang Wu*. Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA. Frontiers in Pharmacology,2019,10:4. [5] Ruiyan Pan, Yadan Zhang, Meng Zheng, Baoxia Zang, Ming Jin*. Hydroxysafflor yellow A suppresses MRC-5 cell activation induced by TGF-β1 by blocking TGF-β1 binding to TβRII. Frontiers in Pharmacology,2017,11;8:264.
|
Copyright © 潍坊医学院药学院 技术支持:恒优科技
地址:山东省潍坊市潍城区宝通西街7166号 邮编:261053